18 and older, any sex, with Parkinson Disease or COPD. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Mean Difference in Distance Walked During 6MWTPrimary· Week 0, week 5, week 10 and week 15
Mean difference in distance walked during the 6MWT (6MWD) derived from the Verily Study Watch and clinician measured distance.
Note: reported outcome is the mean difference in 6MWD between week 0 and week 15 and is determined as the difference between the two clincian measured distances. The walking distance derived from the Verily Study Watch needs to be determined, this is work in progress
Group
Value
95% CI
Parkinson's Disease
33
± 8
COPD
15
± 10
Change in Physical CapacitySecondary· Week 5 until week 15
Change in 6MWD from week 5 until week 15 after aerobic exercise capacity training
Change from baseline in the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS) at week 5, week 10 and week 15. Range 0-199. Higher scores indicate worse function.
note: only the difference in score between week 0 and week 15 is reported
Group
Value
95% CI
Parkinson's Disease
4.5
± 19.2
Change in Depression and Anxiety (HADS)Secondary· Week 0, Week 5, Week 10, Week 15
Change from baseline on the Hospital Anxiety and Depression Scale (HADS) at week 5, week 10 and week 15. Range 0-42. Higher scores indicate worse function
Note: only the difference between week 0 and week 15 is reported
Group
Value
95% CI
Parkinson's Disease
0.6
± 3.6
COPD
0.7
± 3.7
Change in Health Related Quality of Life (PDQ-39)Secondary· Week 0, Week 5, Week 10, Week 15
Change from baseline on the Health related quality of life (PDQ-39) questionnaire at week 5, week 10 and week 15. Range 0-100. HIgher scores indicate better function
Note: only the difference between week 0 and week 15 is reported
Assessment of and change in health related quality of life from baseline and at week 5, week 10 and week 15. Range 0-60. Higher scores indicate worse function
Week 0
Group
Value
95% CI
COPD
2
2 – 2
Week 5
Group
Value
95% CI
COPD
2
1 – 2
Week 10
Group
Value
95% CI
COPD
2
1 – 2
Week 15
Group
Value
95% CI
COPD
2
1 – 2
Medical Research Council Dyspnea (mMRC)Secondary· Week 0, Week 5, Week 10, Week 15
Assessment of dyspnea severity at baseline, week 5, week 10 and week 15. Range 0-4. Higher scores indicate worse function
This test is only completed by the COPD participants as it is a COPD-specific questionnaire.
Week 0
Group
Value
95% CI
COPD
3
2 – 3
Week 5
Group
Value
95% CI
COPD
3
2 – 3
Week 10
Group
Value
95% CI
COPD
3
2 – 3
Week 15
Group
Value
95% CI
COPD
3
2 – 3
Adverse events — posted to ClinicalTrials.gov
Time frame: Adverse event data were collected from baseline to study completion.
Reporting threshold: 2%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The aim of this study is to investigate whether a smartwatch can measure the physical capacity of patients with Parkinson's Disease and COPD in the physiotherapy practice and at home.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06745869 — Effects of Aerobic and Diaphragmatic Exercises on Choir Singers
· NA
· recruiting
NCT06402604 — Stress Reduction in Formerly Preeclamptic Women; Sofa or Sports
· NA
· completed
NCT05202535 — Effect of Aerobic Exercise Training in Obese Adults
· NA
· completed
NCT03984994 — Muscle Capillarization and Sarcopenia
· NA
· completed
NCT04940884 — Supervised Exercise Training Effects on Older Community Dwellers
· NA
· completed
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
NCT07399496 — Accelerated TMS for Apathy in PD
· NA
· recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients
· Phase 1
· recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients
· NA
· recruiting
NCT06848205 — Percept Transitions in FOG and PD
· NA
· recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P
· Phase 2
· recruiting
Other Radboud University Medical Center trials
Trials by the same sponsor.
NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial
· Phase 1
· not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer
· NA
· not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)
· Phase 1
· not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium
· Phase 2, PHASE3
· not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 12 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05756075.